Semaglutide vs tirzepatide: cost and efficacy compared

The efficacy comparison

Both are incretin-based injectables, but they differ mechanistically: semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 agonist. The direct head-to-head, SURMOUNT-5, found tirzepatide reached 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks. Semaglutide's own STEP 1 figure was ~14.9%. On average efficacy, tirzepatide leads — but semaglutide remains highly effective and better-studied over long horizons.

The cost comparison

Compounded semaglutide is frequently priced lower than compounded tirzepatide. In our July 2026 tracking, flat-rate compounded semaglutide runs about $145/month versus roughly $186/month for flat-rate compounded tirzepatide. On the brand side, both are expensive without insurance.

Cost per result

Dividing annual cost by trial-average efficacy is rough but useful. Flat-rate compounded semaglutide (~$1,740/yr ÷ 14.9%) is about $117 per percentage point; flat-rate compounded tirzepatide (~$2,232/yr ÷ 20.2%) is about $110. They're remarkably close — tirzepatide buys more absolute loss, semaglutide costs less per month. An illustrative comparison, not a clinical claim.

Tolerability, track record, and the practical tie-breakers

Efficacy and price get the headlines, but the decision often turns on quieter factors. Tolerability is broadly similar — both dominated by GI side effects that cluster during titration — though individual response varies enough that some people tolerate one markedly better. Because there's no way to predict this in advance, a program allowing a penalty-free switch has real option value. Track record is another tie-breaker: semaglutide has been in widespread use longer, with a deeper real-world literature including the SELECT cardiovascular trial. Availability and pricing consistency round it out: semaglutide programs are slightly more numerous and often a bit cheaper. The honest bottom line is that neither drug is universally better — they occupy different points on the efficacy-cost-evidence frontier. What we can say cleanly is the pricing: flat-rate compounded semaglutide is the lower monthly commitment. Suitability, dose, and switching are clinical decisions for a prescriber.

Frequently asked questions

Availability, switching, and the compounded-market picture

Beyond efficacy and price, the practical availability of each drug shapes real decisions, and here semaglutide has some quiet advantages worth naming. In the compounded telehealth market we track, semaglutide programs are slightly more numerous and geographically broader than tirzepatide programs, which can matter in states with thinner telehealth availability. Both drugs went through brand shortages that reshaped the compounded landscape, and both are now in a narrower regulatory environment where provider transparency matters more than the headline price. On switching: some patients start on one molecule and move to the other based on tolerability or plateau, and a program that permits this without penalty or a fresh signup fee has real value that is invisible at the initial price comparison. The compounded-market reality is that neither drug is a commodity; the pharmacy behind it, the clinical oversight wrapped around it, and the pricing structure determine value as much as the molecule choice. A cost-conscious reader is well served by treating the semaglutide-versus-tirzepatide question as the first of several decisions rather than the only one: which molecule, then which pricing model, then which provider on transparency and support. Getting the molecule right but the provider wrong can cost more, in money and outcome, than the efficacy gap between the two drugs. As always, the molecule and dose decision belongs with a prescriber who knows your history.

What the head-to-head result does and does not settle

It is tempting to read SURMOUNT-5 as ending the debate in tirzepatide favor, but a careful reading is more useful than a verdict. The trial establishes that, on average, in the population studied, tirzepatide produced greater weight loss than semaglutide over 72 weeks. What it does not establish is that tirzepatide is the right choice for any specific individual, because averages conceal wide variation: some people respond strongly to semaglutide and modestly to tirzepatide, and tolerability can differ enough that the drug with the higher average is the wrong drug for a given person who cannot stay on it. The trial also does not speak to compounded versions of either molecule, which are what most cash-pay patients actually buy; it studied the FDA-approved brand products, and compounded formulations have no equivalent head-to-head evidence. Cost enters as a real counterweight to the efficacy gap: if flat-rate compounded semaglutide costs meaningfully less per month and delivers a large share of the benefit, the value calculation can favor it for a budget-conscious patient even though tirzepatide wins on raw efficacy. The honest framing for a comparison site is therefore not to crown a universal winner but to lay out the trade — more absolute weight loss on average with tirzepatide, lower monthly cost and a longer real-world track record with semaglutide — and to route the final decision to a prescriber who can weigh an individual history, insurance situation, and goals. That is the decision this page is built to inform, not replace.

References

1. Aronne LJ, et al. Tirzepatide vs semaglutide (SURMOUNT-5). N Engl J Med. 2025.
2. Wilding JPH, et al. STEP 1. N Engl J Med. 2021.
3. RxCompareHub July 2026 dataset.
4. FDA labeling for Wegovy, Ozempic, Zepbound, Mounjaro.

Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.

Keep reading